1. Introduction {#sec1-cancers-12-00998}
===============

Oral chemotherapy has historically been part of therapeutic regimens for the treatment of cancer \[[@B1-cancers-12-00998],[@B2-cancers-12-00998],[@B3-cancers-12-00998]\]. Over the last years, new oral anti-cancer agents acting as multi-tyrosine kinase inhibitors (TKIs) have dramatically changed patient prognosis and thereby have become standard treatments for several types of tumors \[[@B4-cancers-12-00998],[@B5-cancers-12-00998],[@B6-cancers-12-00998],[@B7-cancers-12-00998],[@B8-cancers-12-00998],[@B9-cancers-12-00998]\]. TKIs targeting the epidermal growth factor receptor (EGFR) (e.g., gefitinib, erlotinib, afatinib, osimertinib) are currently approved for treatment of EGFR mutant non-small cell lung carcinoma (NSCLC), and multi-targeted TKIs (e.g., sunitinib, axitinib, sorafenib, pazopanib) for the treatment of renal cell carcinoma (RCC). Moreover, several new TKIs are currently being tested in clinical trials in several types of solid tumors. The use of oral drugs has a positive impact on patient quality of life for the convenience of self-administration; however, there is a significant risk of drug--drug interactions. The diffusion of these drugs often parallels that of gastric acid suppressants (GAS), such as proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RA). GAS commonly represent part of the complex drug regimen of an average oncologic patient, with an estimated rate of 50% inappropriate PPIs prescriptions, both in hospital and ambulatory settings \[[@B10-cancers-12-00998]\]. Because of the oral administration and pH-dependent solubility of chemotherapy and TKIs, concerns have been raised over the possible effect of co-administering drugs which raise gastric pH\] \[[@B11-cancers-12-00998],[@B12-cancers-12-00998]\]. Chronic acid suppression can reduce the effectiveness of drugs that require an acidic pH for their absorption \[[@B13-cancers-12-00998]\]. Retrospective data suggest that TKI plasma concentration is decreased in patients receiving concomitant GAS therapy with subsequently poorer oncologic outcomes \[[@B14-cancers-12-00998],[@B15-cancers-12-00998]\], however pooled analyses of patients enrolled in clinical trials have shown inconsistent results \[[@B16-cancers-12-00998],[@B17-cancers-12-00998]\].

The aim of our meta-analysis is to define whether concomitant use of GAS therapy (either PPI or H2RA) in patients receiving treatment with oral anti-cancer agents (i.e., chemotherapy or TKIs) is associated with survival outcomes.

2. Results {#sec2-cancers-12-00998}
==========

A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of *n* = 337 not pertinent papers, *n* = 16 were selected for inclusion in quantitative analysis (*n* = 372,418 patients included, with 12% of patients receiving concomitant GAS therapy) \[[@B16-cancers-12-00998],[@B17-cancers-12-00998],[@B18-cancers-12-00998],[@B19-cancers-12-00998],[@B20-cancers-12-00998],[@B21-cancers-12-00998],[@B22-cancers-12-00998],[@B23-cancers-12-00998],[@B24-cancers-12-00998],[@B25-cancers-12-00998],[@B26-cancers-12-00998],[@B27-cancers-12-00998],[@B28-cancers-12-00998],[@B29-cancers-12-00998],[@B30-cancers-12-00998],[@B31-cancers-12-00998]\]. The search results and characteristics of the included studies are presented in [Figure 1](#cancers-12-00998-f001){ref-type="fig"} and [Table 1](#cancers-12-00998-t001){ref-type="table"} and [Table 2](#cancers-12-00998-t002){ref-type="table"}.

All studies were retrospective except for a pooled analysis of phase 2--3 studies by Lalani et al. \[[@B16-cancers-12-00998]\] and a secondary analysis of a randomized prospective trial by Chu et al. \[[@B19-cancers-12-00998]\]. Oncologic treatment consisted of oral TKIs in *n* = 11 studies, while in *n* = 4 studies patients received oral chemotherapy (i.e., capecitabine); one study did not include information regarding the type of study drugs. Oncologic diagnoses were cancers of the gastrointestinal tract (GI, *n* = 5 studies), RCC (*n* = 3 studies), NSCLC (*n* = 5 studies), and soft tissue sarcomas or mixed histologies solid tumors in *n* = 3 studies. Quality according to NOS scale was moderate (range 5--8; median 6).

2.1. Overall Survival and Progression-Free Survival with GAS vs. no GAS {#sec2dot1-cancers-12-00998}
-----------------------------------------------------------------------

*N* = 15 studies reported data on OS. Because the heterogeneity test showed a high level of heterogeneity (I^2^ = 68%, *p* \< 0.01) among studies, a random effects model was used for the analysis. The OS of patients receiving concomitant GAS therapy was significantly worse (HR = 1.31, 95%CI: 1.20--1.43; *p* \< 0.01; [Figure 2](#cancers-12-00998-f002){ref-type="fig"}) compared to those of patients not receiving GAS. Similarly, the use of GAS reduced PFS in *n* = 13 studies that reported data on PFS (HR = 1.3, 95%CI 1.07--1.57; *p* \< 0.007; [Figure 3](#cancers-12-00998-f003){ref-type="fig"}). Heterogeneity was high (I^2^ = 74%), so a random effects model was used.

2.2. Subgroup Analysis {#sec2dot2-cancers-12-00998}
----------------------

In a separate analysis of studies involving patients treated with TKIs, the use of concomitant GAS was similarly associated with poorer OS (HR = 1.35, 95%CI 1.16--1.56; *p* \< 0.01). Similarly, capecitabine assumption with GAS resulted in increased mortality (HR = 1.37, 95%CI 1.1--1.7; *p* \< 0.01). We also searched for a distinct correlation of concomitant GAS in different tumor types: only studies of EGFR-mutated NSCLC patients receiving TKIs and either PPIs or H2RAs and those with GI cancers receiving all PPIs and oral chemotherapy retained a significant correlation between GAS and poor survival (HR = 1.47, 95%CI 1.27--1.71; *p* \< 0.01 and HR = 1.3, 95%CI 1.02--1.66; *p* = 0.04), while in the case of renal cell carcinoma, the correlation between GAS assumption and reduced survival was missing. In patients with lung cancer on anti-EGFR, regression between H2RA and HR for OS was not significant, so the contribution of H2RA does not seem relevant for the final outcome.

In some studies, both PPIs and H2RAs were administered. After exclusion of these studies, *n* = 7 publications included only patients taking PPIs, and HR for OS was similar to the whole population (HR = 1.22, 95%CI 1.09--1.36; *p* \< 0.01). In studies that reported median follow-up (*n* = 6), OS was still poorer in patients taking GAS (HR = 1.29, 95%CI 1.27--1.31; *p* \< 0.01).

2.3. Overall Response Rate {#sec2dot3-cancers-12-00998}
--------------------------

In few studies with data available, PPIs did not influence ORR (OR = 0.89, 95%CI 0.53--1.47; *p* = 0.64, [Figure 4](#cancers-12-00998-f004){ref-type="fig"}).

2.4. Publication Bias {#sec2dot4-cancers-12-00998}
---------------------

A funnel plot was used to assess publication bias in the studies evaluating OS with concomitant GAS versus no GAS therapy in cancer patients. No publication bias was detected. Furthermore, Egger's test was not significant (*p* = 0.39) ([Figure 5](#cancers-12-00998-f005){ref-type="fig"}).

3. Discussion {#sec3-cancers-12-00998}
=============

This is the first meta-analysis exploring the role of concomitant GAS therapy during administration of oral anti-cancer agents for treatment of solid tumors. According to our results, GAS therapy seems to negatively impact on OS and PFS, while it has no impact on ORR.

GAS, and above all PPIs, are among the most commonly prescribed drugs worldwide. Their principal application is treatment of gastroesophageal inflammatory syndromes, such as gastroesophageal reflux disease, esophagitis, and peptic ulcer disease \[[@B32-cancers-12-00998]\]. Given their mild toxicity profile, the use of PPIs has spread over the last 20 years, and we are now facing an overuse in patients with benign conditions or who do not need this specific therapy. Recently, various studies have related PPI use to increased incidence of respiratory tract and *Clostridium difficile* infections, mainly related to an altered commensal intestinal microbiome, as a consequence of raised gastric pH and bacterial overgrowth \[[@B33-cancers-12-00998]\].

The clinical impact of concomitant use of GAS therapy and oral anti-cancer agents remains controversial. Numerous pharmacokinetic studies have addressed this question, showing a possible detrimental effect of GAS on oral anti-cancer drug absorption. However, this phenomenon varies according not only to the drugs analyzed, but depends also on specific drug--drug interactions differing among drugs of the same class \[[@B11-cancers-12-00998],[@B12-cancers-12-00998],[@B34-cancers-12-00998],[@B35-cancers-12-00998]\]. As an example, Egorin et al. showed that PPIs may significantly decrease dasatinib plasmatic levels, while they do not impact on imatinib levels \[[@B34-cancers-12-00998]\]. A similar effect was shown in a small series of patients using concomitant GAS and erlotinib \[[@B11-cancers-12-00998]\], but was not confirmed by data of patients included in the BR.21 trial database \[[@B35-cancers-12-00998]\]. This retrospective analysis on clinical outcomes of patients receiving concomitant GAS and erlotinib showed no differences in plasma drug levels and survival outcomes compared with patients who did not take concomitant GAS \[[@B35-cancers-12-00998]\]. However, the pH-dependent absorption of erlotinib was confirmed in a randomized pharmacokinetic study, which demonstrated that concomitant Cola intake led to a clinically relevant increase in erlotinib bioavailability during esomeprazole treatment due to a temporarily lowered intragastric pH \[[@B36-cancers-12-00998]\]. Analyses on the pharmacokinetics of different TKIs showed that afatinib is highly soluble throughout the physiologic pH range and may therefore have fewer interactions with GAS, compared with gefitinib or erlotinib \[[@B37-cancers-12-00998]\]. A similar effect was observed for osimertinib, where plasmatic levels were not determined by food or PPI co-administration \[[@B12-cancers-12-00998]\]. With our meta-analysis, we reported a significant correlation between GAS and poor survival only for the NSCLC and CRC subgroups, while there was no significant impact on survival when RCC series were considered. A possible explanation may be found in the difference between oral TKIs used in NSCLCs and RCCs. Indeed, TKIs used in lung cancer own anti-EGFR activity (gefitinib and erlotinib), while TKIs used in RCCs have mainly anti-vascular endothelial growth factor (VEGF) properties (sunitinib, sorafenib, axitinib and pazopanib). Moreover, our results are consistent with findings of a previous pooled analysis of metastatic RCC patients treated in phase II and III trials. Indeed, OS results were similar between PPI and non-PPI users in the case of anti-VEGF TKI use \[[@B16-cancers-12-00998]\].

There are two main concerns related to alterations in pharmacokinetics during concomitant GAS therapy. The first is that combined use of PPIs and TKIs may increase the treatment-related adverse events (AEs) of both drugs. Although intuitive, this mechanism is also controversial: in a recent report from Cho et al., concomitant GAS therapy increased gefitinib-induced hepatotoxicity \[[@B38-cancers-12-00998]\]. However, another case series of patients treated with gefitinib and erlotinib did not show differences in the incidence of cutaneous AEs and diarrhea, when comparing patients receiving concomitant GAS to those who did not \[[@B30-cancers-12-00998]\]. Similar reports of patients undergoing concomitant capecitabine and PPIs showed that rates of treatment discontinuation and/or dose reduction due to toxicities were comparable to that of patients not receiving GAS therapy \[[@B20-cancers-12-00998],[@B29-cancers-12-00998]\].

The second important issue lies in the potentially reduced absorption and subsequent compromised anti-cancer drug effect. Reports from the literature on this topic mainly consist of case series, reporting heterogeneous data in terms of patient populations, anti-cancer drugs (chemotherapy, TKIs), GAS therapy (PPIs, H2RA, or both), and outcomes (survival vs response vs AEs incidence). Our meta-analysis confirmed that concomitant GAS can have a negative impact on PFS and OS, however without significant effects on ORR. One of the possible reasons for the worse survival outcomes is that patients requiring GAS are older and have various comorbidities (e.g., cardiovascular disease requiring aspirin and therefore PPI therapy). Another theory is that concomitant GAS therapy reduces serum levels of anti-cancer drugs under the therapeutic threshold, thus increasing the risk for distant metastasis and disease progression. Although previous studies show that TKIs are effective even at low serum levels, it is recognized that the cerebrospinal fluid penetration rate of first-generation TKIs is only around 2% \[[@B39-cancers-12-00998]\]. Thus, the concomitant use of drugs reducing gastric absorption of TKIs may further reduce their serum levels to an insufficient plasmatic concentration \[[@B40-cancers-12-00998]\].

Given these two considerations, we can speculate that concomitant administration of GAS drugs during anti-cancer therapy does not significantly affect ORR because of the maintenance of an adequate therapeutic anti-cancer threshold. On the contrary, over a long period, GAS administration might affect therapeutic activity of anti-cancer drugs. This element, combined with risk factors of age and comorbidities of patients treated with GAS, might explain the worsened survival rates for this subgroup of patients. The relatively low number of studies reporting complete OS results (6 out of 16 analyzed studies), however, makes the interpretation of this result even more speculative. The observations of our analysis are only hypotheses-generating: data available so far can be used as starting points to carry on further prospective parallel data collection and analyses in clinical practice.

Our meta-analysis has some intrinsic limitations. First of all, patients taking PPIs may have an intrinsically poor performance status and/or chronic conditions that require continuous GAS. Secondly, use of PPIs was not offered with a randomized design so that patients treated with PPIs may have suffered from concomitant gastritis/dyspepsia and/or may have taken steroids for supportive care, consequently needing chronic GAS therapy. Thirdly, there is uncertainty regarding the correct administration of PPIs right before antitumoral treatment.

Moreover, PPIs and H2RAs have different mechanisms of action and potency. Due to the heterogeneity of studies analyzed, we only have the results of a subgroup analysis of studies analyzing the effect of single GAS therapy (i.e., PPIs or H2RAs), with only limited data on length of overlapping therapies.

Finally, other pharmacological interactions (e.g., with the CYP3A4 citocrome) may have reduced plasmatic concentration of anti-EGFR agents.

4. Materials and Methods {#sec4-cancers-12-00998}
========================

This study followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group guidelines and checklist \[[@B41-cancers-12-00998]\] ([Figure 1](#cancers-12-00998-f001){ref-type="fig"}, [Table 3](#cancers-12-00998-t003){ref-type="table"}).

4.1. Data Extraction and Quality Assessment {#sec4dot1-cancers-12-00998}
-------------------------------------------

A protocol was defined prior to the search including the population criteria, description of oncologic treatments, comparisons, and outcomes of interest. A systematic literature search was performed using PubMed (MEDLINE), EMBASE and The Cochrane Library. The search was performed comprehensively using several databases from each one's earliest start until 1st August 2019. We sought to identify all English language research evaluating the effect of GAS use on the outcomes of patients receiving concomitant oral chemotherapy or TKIs for solid tumors. For the process of evidence acquisition, the literature was queried using the following terms \[MeSH\]: "gastric acid suppressant" OR "proton pump inhibitors", and "chemotherapy" or "tyrosine kinase inhibitors" AND "carcinoma" or "cancer" AND "survival". References of included studies were hand-searched in order to identify potentially relevant adjunctive papers. For each study we extracted the following information, if available: number of patients, baseline patient characteristics, data regarding oncologic treatments, progression-free (PFS) or recurrence-free (RFS) survivals and overall survival (OS) or the corresponding HRs, and overall response rates (ORRs) in the 2 arms.

Two independent reviewers (AI and FP) evaluated all studies in order to verify the inclusion criteria. Study selection was conducted with a two-phase screening. First level screening excluded titles and abstracts meeting the following criteria: (a) case reports, letters, comments, and reviews not reporting original data; (b) in vivo and/or in vitro studies; (c) studies involving fewer than 10 patients; and (d) language publication other than English. Studies matching inclusion criteria were obtained in the complete form and reviewed in their full-text version for an advanced assessment. Second level full-text screening was performed in order to include studies with the following criteria: (1) studies involving patients with solid tumors receiving oral chemotherapy or TKIs; (2) studies reporting outcomes of patients receiving concomitant GAS therapy compared to those who did not; (3) information regarding HRs or survival curves for OS and/or PFS and/or ORRs for patients using GAS compared to those who did not. Differences of opinion were resolved by agreement between the reviewers. Study quality was independently evaluated using the Newcastle-Ottawa Quality Assessment scale for case-control studies \[[@B42-cancers-12-00998]\]. Disagreement was also resolved by consultation and consensus.

4.2. Statistical Analysis {#sec4dot2-cancers-12-00998}
-------------------------

The primary outcome of interest was OS. The secondary endpoints were PFS and ORR. The HRs and 95% CIs from each study were either extracted directly from original papers or calculated using Kaplan--Meier curves based on the method of Tierney et al \[[@B43-cancers-12-00998]\]. Random effects models with inverse variance weighting were calculated using Review Manager (RevMan 5.3, The Nordic Cochrane Center, Copenhagen, Denmark). The heterogeneity of the underlying population was assessed using the Q-statistic and I^2^ test. For the interpretation, I^2^ values greater than 50% were considered to be heterogeneous \[[@B44-cancers-12-00998]\]. Publication bias was assessed by visually evaluating a funnel plot (Begg's and Egger's test, [Figure 4](#cancers-12-00998-f004){ref-type="fig"}).

5. Conclusions {#sec5-cancers-12-00998}
==============

The use of GAS during cancer therapy with capecitabine or TKIs should be offered with caution because it may result in a reduction of anti-cancer treatment and may significantly affect therapeutic outcomes. In our meta-analysis, we observed a significantly worse OS and PFS in patients receiving GAS during cancer treatment with anti-EGFR TKIs or capecitabine-based regimens in GI cancers and NSCLC. In conclusion, except for clear clinical reasons (concomitant use of steroids/non-steroidal anti-inflammatory drugs, severe gastroesophageal reflux disease/gastritis/peptic ulcer) GAS should be avoided during treatment with oral anti-cancer drugs for solid tumors.
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cancers-12-00998-t001_Table 1

###### 

Main characteristics of the included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                               Principal Institution(s) Involved                                                                                     Study Design                               Study Period   Number of Patients   Patients' Disease Characteristics       Oral Anti-cancer Drug   Type of GAS
  ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------ -------------- -------------------- --------------------------------------- ----------------------- -------------
  Ha, 2014 \[[@B23-cancers-12-00998]\]                 Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada                                             retrospective                              2006--2013     383                  mRCC                                    Sunitinib               PPI

  Sun, 2016 \[[@B27-cancers-12-00998]\]                Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada                                             retrospective                              2008--2012     298                  Early stage CRC                         Capecitabine            PPI

  Chu, 2015 \[[@B19-cancers-12-00998]\]                Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada                                             retrospective                              2007--2012     507                  EGFR mutant advanced NSCLC              Erlotinib               PPI, H2RA

  Zenke, 2016 \[[@B30-cancers-12-00998]\]              Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan                                 retrospective                              2008--2011     130                  EGFR mutant advanced NSCLC              Gefitinib\              PPI, H2RA
                                                                                                                                                                                                                                                                                                    Erlotinib               

  Kumarakulasinghe, 2016 \[[@B24-cancers-12-00998]\]   Department of Haematology-Oncology, National University Cancer Institute, Singapore                                   retrospective                              2008--2013     157                  EGFR mutant advanced NSCLC              Gefitinib\              PPI, H2RA
                                                                                                                                                                                                                                                                                                    Erlotinib               

  Chen, 2016 \[[@B18-cancers-12-00998]\]               Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan   retrospective                              2010--2013     269                  EGFR mutant advanced NSCLC              EGFR TKIs NOS           PPI

  Graham, 2016 \[[@B21-cancers-12-00998]\]             Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston                           retrospective                              2005--2011     117                  CRC                                     NA                      PPI

  Chu, 2017 \[[@B20-cancers-12-00998]\]                Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada                                             retrospective analysis (phase III trial)   2008--2012     545                  GEJC                                    Capecitabine            PPI

  Zhang, 2017 \[[@B31-cancers-12-00998]\]              Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China                                     retrospective                              2008--2016     125                  CRC                                     Capecitabine            PPI

  Lalani, 2017 \[[@B16-cancers-12-00998]\]             Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA                                             pooled analysis (phase II/III studies)     2003--2013     2188                 mRCC                                    Sunitinib\              PPI
                                                                                                                                                                                                                                                                                                    Axitinib\               
                                                                                                                                                                                                                                                                                                    Sorafenib               

  McAlister, 2018 \[[@B25-cancers-12-00998]\]          Vanderbilt-Ingram Cancer Center, Nashville, USA                                                                       retrospective                              2010--2015     90                   mRCC                                    Pazopanib               PPI, H2RA

  Tvingsholm, 2018 \[[@B28-cancers-12-00998]\]         Danish Cancer Society Research Center, Copenhagen, Denmark (Danish Cancer Registry)                                   retrospective                              1995--2011     353,071              Solid Tumors (Danish Cancer Registry)   NA                      PPI

  Wong, 2019 \[[@B29-cancers-12-00998]\]               Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada                                             retrospective                              2004--2013     389                  stage II-III CRC                        Capecitabine            PPI

  Fang, 2019 \[[@B21-cancers-12-00998]\]               Chang Gung Memorial Hospital, Chiayi Branch, Puzi City, Chiayi County, Taiwan                                         retrospective                              1997--2013     1278                 EGFR mutant advanced NSCLC              Gefitinib               PPI

  Mir, 2019 \[[@B17-cancers-12-00998]\]                Gustave Roussy, Sarcoma Group, Villejuif, France                                                                      retrospective                              2005--2007\    333                  STS                                     Pazopanib               PPI, H2RA
                                                                                                                                                                                                                        2008--2010                                                                                          

  Sharma, 2019 \[[@B26-cancers-12-00998]\]             The University of Mississippi, Oxford, Mississippi, USA (SEER Database)                                               retrospective                              2007--2012     12,538               Solid Tumors (SEER Database)            TKIs                    PPI
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend: CRC, colorectal cancer; GEJC, gastro-esophageal junction cancer; EGFR, epidermal growth factor receptor; GAS, gastric acid suppressants; H2RA, histamine-2 receptor antagonists; NA, not applicable; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PPI, proton-pump inhibitors; mRCC, metastatic renal cell carcinoma; SEER, Surveillance, Epidemiology, and End Results; STS, soft-tissue sarcoma; TKI, tyrosine kinase inhibitors; USA, United States of America.

cancers-12-00998-t002_Table 2

###### 

Response and survival outcomes in the analyzed studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, Year                                        Median Follow-Up, Months   Criteria for Overlapping between GAS and Anti-cancer Treatment (Time Overlapping %)   Therapeutic Approach, *n* (%)   ORR     OS HR (95% CI) \*   PFS HR (95% CI) \*   Type of Analysis   Quality NOS Score
  ---------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------- ------------------------------- ------- ------------------- -------------------- ------------------ -------------------
  Ha, 2014 \[[@B23-cancers-12-00998]\]                 NA                                                                                                               GAS: 45 (20%)                   NA      1.43\               1.36\                UVA                5
                                                                                                                                                                                                                (0.95--2.15)        (0.92--2.01)                            

  100                                                  No GAS: 186 (80%)          NA                                                                                                                                                                                        

  Sun, 2016 \[[@B27-cancers-12-00998]\]                NA                                                                                                               GAS: 77 (26%)                   NA      0.94\               0.61\                MVA                5
                                                                                                                                                                                                                (0.49--1.78)        (0.34--1.08)                            

  Any PPI prescription                                 No GAS: 202 (74%)          NA                                                                                                                                                                                        

  Chu, 2015 \[[@B19-cancers-12-00998]\]                NA                                                                                                               GAS: 124 (25%)                  5.6%    1.37\               1.83\                MVA                6
                                                                                                                                                                                                                (1.11--1.69)        (1.48--2.25)                            

  ≥20                                                  No GAS: 383 (75%)          18.5%                                                                                                                                                                                     

  Zenke, 2016 \[[@B30-cancers-12-00998]\]              36 (10.1--85.2)                                                                                                  GAS: 47 (36%)                   64%     1.41\               1.15\                MVA                7
                                                                                                                                                                                                                (0.83--2.35)        (0.73--1.79)                            

  PPI/H2RA sequentially or concurrently to anti-EGFR   No GAS: 83 (64%)           63%                                                                                                                                                                                       

  Kumarakulasinghe, 2016 \[[@B24-cancers-12-00998]\]   50                                                                                                               GAS: 55 (35%)                   NA      1.37\               1.47\                MVA                7
                                                                                                                                                                                                                (0.89--2.12)        (0.92--2.35)                            

  ≥30                                                  No GAS: 102 (65%)          NA                                                                                                                                                                                        

  Chen, 2016 \[[@B18-cancers-12-00998]\]               24.5                                                                                                             GAS: 57 (21%)                   NA      2.27\               2.00\                MVA                6
                                                                                                                                                                                                                (1.26--4.11)        (0.96--4.17)                            

  ≥30                                                  No GAS: 212 (79%)          NA                                                                                                                                                                                        

  Graham, 2016 \[[@B21-cancers-12-00998]\]             NA                                                                                                               GAS: 117 (9%)                   NA      1.34\               NA                   MVA                7
                                                                                                                                                                                                                (1.01--1.79)                                                

  NA                                                   No GAS: 1187 (91%)         NA                                                                                                                                                                                        

  Chu, 2017 \[[@B20-cancers-12-00998]\]                NA                                                                                                               GAS: 119 (44%)                  36%     1.41\               1.68\                MVA                5
                                                                                                                                                                                                                (1.11--1.71)        (1.42--1.94)                            

  ≥20                                                  No GAS: 155 (56%)          42%                                                                                                                                                                                       

  Zhang, 2017 \[[@B31-cancers-12-00998]\]              66                                                                                                               GAS: 29 (23%)                   52.2%   0.30\               0.37\                UVA \*, MVA        7
                                                                                                                                                                                                                (0.09--0.99)        (0.11--1.23) \*                         

  ≥200 mg PPI                                          No GAS: 96 (77%)           36.5%                                                                                                                                                                                     

  Lalani, 2017 \[[@B16-cancers-12-00998]\]             NA                                                                                                               GAS: 120 (5%)                   23.3%   1.05\               1.02\                MVA                5
                                                                                                                                                                                                                (0.77--1.44)        (0.79--1.30)                            

  ≥1 dose PPI                                          No GAS: 2068(95%)          27.4%                                                                                                                                                                                     

  McAlister, 2018 \[[@B25-cancers-12-00998]\]          NA                                                                                                               GAS: 66 (73%)                   NA      0.99\               1.25\                MVA                5
                                                                                                                                                                                                                (0.51--1.93)        (0.76--2.07)                            

  ≥90 days                                             No GAS: 24 (27%)           NA                                                                                                                                                                                        

  Tvingsholm, 2018 \[[@B28-cancers-12-00998]\]         1.52 (0.50--3.89)                                                                                                GAS: 41,218 (11.7%)             NA      1.29\               NA                   MVA                7
                                                                                                                                                                                                                (1.27--1.31)                                                

  ≥2 prescriptions within 6 months                     No GAS: 311,853 (88.3%)    NA                                                                                                                                                                                        

  Wong, 2019 \[[@B29-cancers-12-00998]\]               NA                                                                                                               GAS: 50 (23.4%)                 NA      1.68\               2.20\                MVA                5
                                                                                                                                                                                                                (0.75--3.80)        (1.14--4.25)                            

  Any time PPI during capecitabine                     No GAS: 164 (76.6%)        NA                                                                                                                                                                                        

  Fang, 2019 \[[@B21-cancers-12-00998]\]               NA                                                                                                               GAS: 309 (24%)                  NA      1.67\               0.99\                MVA                7
                                                                                                                                                                                                                (1.33--2.09)        (0.80--1.23)                            

  ≥20                                                  No GAS: 969 (76%)          NA                                                                                                                                                                                        

  Mir, 2019 \[[@B17-cancers-12-00998]\]                27.6 (22.9--35.4)                                                                                                GAS: 59 (18%)                   NA      1.81\               1.49\                MVA                6
                                                                                                                                                                                                                (1.31--2.49)        (1.11--1.99)                            

  ≥80                                                  No GAS: 273 (82%)          NA                                                                                                                                                                                        

  Sharma, 2019 \[[@B26-cancers-12-00998]\]             NA                                                                                                               GAS: 2843 (22.7%)               NA      1.10\               NA                   MVA                8
                                                                                                                                                                                                                (1.04--1.17)                                                

  ≥30 days within 3 months                             No GAS: 9695 (77.3%)       NA                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* When both univariate and multivariate analyses were performed, HR results of multivariate analyses are reported. Legend: CI, confidence interval; GAS, gastric acid suppressants; HR, hazard ratio; NA, not available; NA, not determined; NOS, Newcastle-Ottawa Scale; MVA, multivariate analysis; ORR, overall response rate; OS, overall survival; PFS, progression free survival; UVA, univariate analysis.
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###### 

MOOSE Checklist for Meta-analyses of Observational Studies.

  Item No                                       Recommendation                                                                                                                                                                                                                                                                   Reported on Page No
  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reporting of background should include                                                                                                                                                                                                                                                                                         
  1                                             Problem definition                                                                                                                                                                                                                                                               1,2
  2                                             Hypothesis statement                                                                                                                                                                                                                                                             1,2
  3                                             Description of study outcome(s)                                                                                                                                                                                                                                                  11
  4                                             Type of exposure or intervention used                                                                                                                                                                                                                                            11
  5                                             Type of study designs used                                                                                                                                                                                                                                                       11
  6                                             Study population                                                                                                                                                                                                                                                                 11
  Reporting of search strategy should include                                                                                                                                                                                                                                                                                    
  7                                             Qualifications of searchers (e.g., librarians and investigators)                                                                                                                                                                                                                 1
  8                                             Search strategy, including time period included in the synthesis and key words                                                                                                                                                                                                   11
  9                                             Effort to include all available studies, including contact with authors                                                                                                                                                                                                          11
  10                                            Databases and registries searched                                                                                                                                                                                                                                                11
  11                                            Search software used, name and version, including special features used (e.g., explosion)                                                                                                                                                                                        11
  12                                            Use of hand searching (e.g., reference lists of obtained articles)                                                                                                                                                                                                               11, [Figure 1](#cancers-12-00998-f001){ref-type="fig"}
  13                                            List of citations located and those excluded, including justification                                                                                                                                                                                                            11, [Figure 1](#cancers-12-00998-f001){ref-type="fig"}
  14                                            Method of addressing articles published in languages other than English                                                                                                                                                                                                          11
  15                                            Method of handling abstracts and unpublished studies                                                                                                                                                                                                                             11
  16                                            Description of any contact with authors                                                                                                                                                                                                                                          11
  Reporting of methods should include                                                                                                                                                                                                                                                                                            
  17                                            Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested                                                                                                                                                                       11
  18                                            Rationale for the selection and coding of data (e.g., sound clinical principles or convenience)                                                                                                                                                                                  11
  19                                            Documentation of how data were classified and coded (e.g., multiple raters, blinding and interrater reliability)                                                                                                                                                                 11
  20                                            Assessment of confounding (e.g., comparability of cases and controls in studies where appropriate)                                                                                                                                                                               11
  21                                            Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results                                                                                                                                       11
  22                                            Assessment of heterogeneity                                                                                                                                                                                                                                                      7,8, [Figure 5](#cancers-12-00998-f005){ref-type="fig"}
  23                                            Description of statistical methods (e.g., complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated   12
  24                                            Provision of appropriate tables and graphics                                                                                                                                                                                                                                     [Figure 1](#cancers-12-00998-f001){ref-type="fig"}
  Reporting of results should include                                                                                                                                                                                                                                                                                            
  25                                            Graphic summarizing individual study estimates and overall estimate                                                                                                                                                                                                              [Table 1](#cancers-12-00998-t001){ref-type="table"} and [Table 2](#cancers-12-00998-t002){ref-type="table"}
  26                                            Table giving descriptive information for each study included                                                                                                                                                                                                                     [Table 1](#cancers-12-00998-t001){ref-type="table"} and [Table 2](#cancers-12-00998-t002){ref-type="table"}
  27                                            Results of sensitivity testing (e.g., subgroup analysis)                                                                                                                                                                                                                         2, 6--8, [Figure 2](#cancers-12-00998-f002){ref-type="fig"}, [Figure 3](#cancers-12-00998-f003){ref-type="fig"} and [Figure 4](#cancers-12-00998-f004){ref-type="fig"}
  28                                            Indication of statistical uncertainty of findings                                                                                                                                                                                                                                7,8, [Figure 5](#cancers-12-00998-f005){ref-type="fig"}
  29                                            Quantitative assessment of bias (e.g., publication bias)                                                                                                                                                                                                                         7,8, [Figure 5](#cancers-12-00998-f005){ref-type="fig"}
  30                                            Justification for exclusion (e.g., exclusion of non-English language citations)                                                                                                                                                                                                  [Figure 1](#cancers-12-00998-f001){ref-type="fig"}, 11
  31                                            Assessment of quality of included studies                                                                                                                                                                                                                                        11
  Reporting of conclusions should include                                                                                                                                                                                                                                                                                        
  32                                            Consideration of alternative explanations for observed results                                                                                                                                                                                                                   8,9
  33                                            Generalization of the conclusions (i.e., appropriate for the data presented and within the domain of the literature review)                                                                                                                                                      12
  34                                            Guidelines for future research                                                                                                                                                                                                                                                   8,9,11
  35                                            Disclosure of funding source                                                                                                                                                                                                                                                     12
